Is the amyloid concentration in AD clinical trials rational given lecanemab's approval, or should the field pivot aggressively to neuroinflammation?
Clinical Trial Landscaping for Alzheimer's Disease Therapeutics
Computing debate synthesis…
Debate Transcript
No transcript rounds recorded for this debate.